Virologica Sinica

, Volume 33, Issue 6, pp 538–544 | Cite as

In Vitro Anti-hepatitis B Virus Activity of 2′,3′-Dideoxyguanosine

  • Pinghu Zhang
  • Shuo Zhai
  • Jinhong Chang
  • Ju-Tao GuoEmail author
Research Article


2′,3′-dideoxyguanosine (DoG) has been demonstrated to inhibit duck hepatitis B virus (DHBV) replication in vivo in a duck model of HBV infection. In the current study, the in vitro antiviral effects of DoG on human and animal hepadnaviruses were investigated. Our results showed that DoG effectively inhibited HBV, DHBV, and woodchuck hepatitis virus (WHV) replication in hepatocyte-derived cells in a dose-dependent manner, with 50% effective concentrations (EC50) of 0.3 ± 0.05, 6.82 ± 0.25, and 23.0 ± 1.5 μmol/L, respectively. Similar to other hepadnaviral DNA polymerase inhibitors, DoG did not alter the levels of intracellular viral RNA but induced the accumulation of a less-than-full-length viral RNA species, which was recently demonstrated to be generated by RNase H cleavage of pgRNA. Furthermore, using a transient transfection assay, DoG showed similar antiviral activity against HBV wild-type, 3TC-resistant rtA181V, and adefovir-resistant rtN236T mutants. Our results suggest that DoG has potential as a nucleoside analogue drug with anti-HBV activity.


HBV Woodchuck hepatitis virus (WHV) Hepatitis B Antiviral Nucleoside analogues 



The work was supported in part by the Program for New Century Excellent Talents in University (Program No. NCET-12-0975); by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry; and by Jiangsu Overseas research & training program for University Prominent Young and Middle-aged Teachers and Presidents (for Pinghu Zhang); Qinghai Province High-end Innovative Talent Thousand Talents Program (for Pinghu Zhang).

Author Contributions

PZ mainly contributed to the design, acquisition, analysis, and interpretation of data for this work; ZS contributed to the sequencing of viral RNA species; JC and JTG contributed to the experimental design and data interpretation of this work.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Animal and Human Rights Statement

The authors declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.


  1. Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK, Kwon SY, Kim KH (2014) The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol 88:6518–6805CrossRefGoogle Scholar
  2. Busso ME, Resnick L, Yang BH, Mian AM (1990) Cellular pharmacology and anti-HIV activity of 2′,3′-dideoxyguanosine. AIDS Res Hum Retrovir 6:1139–1146CrossRefGoogle Scholar
  3. Campagna MR, Liu F, Mao R, Mills C, Cai D, Guo F, Zhao X, Ye H, Cuconati A, Guo H, Chang J, Xu X, Block TM, Guo JT (2013) Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids. J Virol 87:6931–6942CrossRefGoogle Scholar
  4. Chen ZY, Cheng AC, Wang MS, Xu DW, Zeng W, Li Z (2007) Antiviral effects of PNA in duck hepatitis B virus infection model. Acta Pharmacol Sin 28:1652–1658CrossRefGoogle Scholar
  5. Chinese Society of Hepatology and Chinese Society of Infectious Diseases (2011) Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Liuxing Bingxue Zazhi 32:405–415 (in Chinese)Google Scholar
  6. Christian T, Henry LYC, Anna L (2014) Hepatitis B virus infection. Lancet 384:2053–2063CrossRefGoogle Scholar
  7. Condreav LD, Aldrich CE, Coates L, Mason WS, Wu TT (1990) Efficient duck hepatitis B virus production by an avian liver tumor cell line. J Virol 64:3249–3258Google Scholar
  8. European Association for The Study of The Liver (2012) EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 57:167–185CrossRefGoogle Scholar
  9. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT (2007) Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol 81:12472–12484CrossRefGoogle Scholar
  10. Guo JT, Pryce M, Wang X, Barrasa MI, Hu J, Seeger C (2013) Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol 77:1885–1893CrossRefGoogle Scholar
  11. Guo XH, Wu JS, Wei FL, Ouyang YB, Li Q, Liu K, Wang YJ, Zhang YL, Chen DX (2018) Trends in hepatitis B virus resistance to nucleoside/nucleotide analogs in North China from 2009 to 2016: a retrospective study. Int J Antimicrob Agents. Google Scholar
  12. Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F (2006) In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2′,3′-dideoxy-3′-fluoroguanosine. Antimicrob Agents Chemother 50:955–961CrossRefGoogle Scholar
  13. Jeffrey DM, Raymond FS, John WM, Nicolas SC (2014) Molecular mechanism of HIV-1 resistance to 3′-azido-2′3′-dideoxyguanosine. Antiviral Res 101:62–67CrossRefGoogle Scholar
  14. Jones SA, Murakami E, Delaney W, Furman P, Hu J (2013) Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine. Antimicrob Agents Chemother 57:4181–4189CrossRefGoogle Scholar
  15. Korba BE, Cote P, Hornbuckle W, Tennant BC, Gerin JL (2000) Treatment of chronic woodchuck hepatitis virus infection in the Eastern woodchuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165–1175CrossRefGoogle Scholar
  16. Ladner SX, Otto MJ, Barker CS, Zaifert K, Wang GH, Guo JT, Seeqer C, King RW (1997) Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41:1715–1720CrossRefGoogle Scholar
  17. Li Z, Huang X, Jiang Z, Xiao Y, Liu C, Zhang L, Shu B, Huang J, Li T, Wang T, Wang F (2008) A sensitive and specific liquid chromatography-mass spectrometry method for determination of metacavir in rat plasma. J Chromatogr B 864:9–14CrossRefGoogle Scholar
  18. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 6:531–561CrossRefGoogle Scholar
  19. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT (2013) Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 9:e1003613CrossRefGoogle Scholar
  20. Meng T, Shi XF, Gong XY, Deng HJ, Huang Y, Shan XF, Shan YL, Huang AL, Long QX (2017) Analysis of the prevalence of drug-resistant hepatitis B virus in patients with antiviral therapy failure in a Chinese tertiary referral liver centre (2010–2014). J Global Antimicrob Resist 8:74–81CrossRefGoogle Scholar
  21. Menne S, Cote PJ (2007) The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 13:104–124CrossRefGoogle Scholar
  22. Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC (2008) Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother 52:3617–3632CrossRefGoogle Scholar
  23. Schinazi RF, Bassit L, Clayton MM, Sun B, Kohler JJ, Obikhod A, Arzumanyan A, Feitelson MA, Barbara R, Antonio B (2012) Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication. Antimicrob Agents Chemother 56:6186–6191CrossRefGoogle Scholar
  24. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ (2015) Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 386:1546–1555CrossRefGoogle Scholar
  25. Staschke KA, Colacino JM (1994) Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J Virol 68:8265–8269Google Scholar
  26. Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Suzuki Y, Kumada H (2014) Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir. Drug Des Devel Ther 8:869–873CrossRefGoogle Scholar
  27. Wang J, Shen T, Huang XB, Renuka Kumar G, Chen XM, Zeng ZZ, Zhang RY, Chen R, Tong Li, Zhang T, Yuan Q, Li PC, Huang Q, Colonno R, Jia JD, Hou JL, McCrae MA, Gao ZL, Ren H, Xia NS, Zhuang H, Lu FM (2016) Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 65:700–710CrossRefGoogle Scholar
  28. Watcharasak C, Carolyn P, Fausta AD, Diane G, Anna SFLK (2011) Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 54:12–18CrossRefGoogle Scholar
  29. Yu W, Goddard C, Clearfield E, Mills C, Xiao T, Guo H, Morrey JD, Motter NE, Zhao K, Block TM, Cuconati A, Xu X (2011) Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem 54:5660–5670CrossRefGoogle Scholar
  30. Zeng W, Cheng AC, Chen ZL, Luo QH, Sun YB, Li Z, Bi FJ (2009) In vivo assessment of mitochondrial toxicity of PNA in Rhesus monkeys after three months of intravenous administration. Acta Pharmacol Sin 30:1666–1673CrossRefGoogle Scholar
  31. Zhang P, Zhang L, Jiang Z, Wang T, Chen H, Xiong Y, Li Z (2010) In vitro mitochondrial toxicity of PNA, a new nucleoside reverse transcriptase inhibitor for treatment of hepatitis B virus. Antimicrob Agents Chemother 54:4887–4892CrossRefGoogle Scholar
  32. Zhang P, Zhang L, Jiang Z, Xiong Y, Chen H, Tao Y, Hu M, Li Z (2011) Evaluation of mitochondrial toxicity in Marmota himalayana treated with PNA, a novel 2′,3′-dideoxyguanosine prodrug for treatment of hepatitis B virus. Antimicrob Agents Chemother 55:1930–1936CrossRefGoogle Scholar
  33. Zhang P, Liu F, Guo F, Zhao Q, Chang J, Guo JT (2016) Characterization of novel hepadnaviral RNA species accumulated in hepatoma cells treated with viral DNA polymerase inhibitors. Antivir Res 131:40–48CrossRefGoogle Scholar
  34. Zhang HY, Liu LG, Ye CY, Chen CH, Hang SX, Zhu Z, Shen HY, Huang ZY, Chen WY, Xue Y (2018) Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010–2016). Virus Genes 54:41–47CrossRefGoogle Scholar
  35. Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K (2009) Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 19:165–176CrossRefGoogle Scholar
  36. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleo(t)ide analogues. Gastroenterology 137:1593–1608CrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Institute of Translational Medicine and Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile DiseasesYangzhou UniversityYangzhouChina
  2. 2.Baruch S. Blumberg Institute, Hepatitis B FoundationDoylestownUSA
  3. 3.Qinghai Himalayan Experimental Animal CenterXiningChina

Personalised recommendations